Recent first-in-human trials include Pheast and Auron, plus new targets from Immunocore and Cero.
ApexOnco Front Page
Recent articles
The companies press on with vilastobart and IMPT-314... up to a point.
The company is to start a first-line phase 3 breast cancer trial of gedatolisib, as second-line data approach.
But the timeline for a US green light is less clear, and the group has a cash crisis.
First-in-human trial initiations include Biocytogen's DM002 and Day One's DAY301.
An anti-integrin β6 ADC and a CDK4 inhibitor shoot for bigger markets.
The private group taps DualityBio for an EGFR x HER3 ADC.
Galapagos distances itself from Gilead, and offers a pure-play oncology cell therapy focus.
